Skip to main content
. 2021 Aug 23;6(11):2830–2839. doi: 10.1016/j.ekir.2021.08.020

Table 1.

Patient baseline characteristics

Parameter All patients
Prior cinacalcet use
P value
Nonusers
Users
N = 253 n = 98 n = 155
Sex
 Male 177 (70.0) 69 (70.4) 108 (69.7) 0.902
Age, yr 60.9 ± 11.4 63.8 ± 11.3 59.2 ± 11.1 0.002
Body mass index, kg/m2 24.6 ± 4.6 25.0 ± 4.5 24.3 ± 4.6 0.202
Primary disease
 Diabetic nephropathy 66 (26.1) 27 (27.6) 39 (25.2) 0.560
 Chronic glomerulonephritis 104 (41.1) 35 (35.7) 69 (44.5)
 Nephrosclerosis 31 (12.3) 13 (13.3) 18 (11.6)
 Other 52 (20.6) 23 (23.5) 29 (18.7)
Duration of dialysis, mo 126.5 ± 86.2 92.6 ± 70.9 147.9 ± 88.3 < 0.001
Type of dialysis
 HD 200 (79.1) 81 (82.7) 119 (76.8) 0.263
 HDF 53 (20.9) 17 (17.3) 36 (23.2)
Dry weight, kg 62.2 ± 13.9 63.3 ± 14.2 61.6 ± 13.7 0.342
Dialysis efficiency, spKt/V 1.50 ± 0.29 1.46 ± 0.28 1.52 ± 0.29 0.092
Use of vitamin D receptor activator
 Users 217 (85.8) 80 (81.6) 137 (88.4) 0.134
 Oral only 81 (32.0) 38 (38.8) 43 (27.7) 0.018
 Parenteral 136 (53.8) 42 (42.9) 94 (60.6)
Intact PTH, pg/ml 374 (298, 472) 336 (278, 415) 390 (311, 511) 0.002
Corrected calcium, mg/dl 9.5 ± 0.6 9.3 ± 0.5 9.6 ± 0.6 < 0.001
Phosphate, mg/dl 5.8 ± 1.3 5.7 ± 1.4 5.8 ± 1.3 0.448
Corrected calcium−phosphate product, mg2/dl2 54.6 ± 12.3 52.9 ± 12.6 55.7 ± 12.1 0.073
Bone-specific alkaline phosphatase, μg/l 17.6 ± 9.9 17.0 ± 8.6 17.9 ± 10.7 0.744
Tartrate-resistant acid phosphatase 5b, mU/dl 783.2 ± 394.5 682.3 ± 348.7 846.9 ± 409.3 < 0.001
Procollagen type 1 N-terminal-propeptide, μg/l 437.3 ± 287.5 363.4 ± 233.1 484.0 ± 308.8 0.002
Fibroblast growth factor 23, pg/ml 13 600 (6130, 28 600) 12 150 (5010, 24 200) 15 300 (6640, 30 700) 0.120
Largest parathyroid gland volume, mm3 332.1 ± 627.1 290.6 ± 613.1 354.7 ± 636.4 0.025

Data are number (%), mean ± SD, or median (interquartile range). ꭓ2 Test (categorical), unpaired t test or Mann–Whitney U test (continuous). HD, hemodialysis; HDF, hemodiafiltration; PTH, parathyroid hormone.